Jefferies upgrades Kodiak Sciences, citing undervaluation and growth potential as Phase 3 trials advance for tarcocimab in ...

Whilst the discovery of the first anti-vascular endothelial growth factor (VEGF ... that demonstrates the need to target other molecular mechanisms and disease pathways. Similarly, fibrosis ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...